Altered MEF2 isoforms in myotonic dystrophy and other neuromuscular disorders

Muscle and Nerve

Volumn 42, Issue 6, 2010, Pages 856-863

  Bachinski, Linda L ^a   Sirito, Mario ^a   Böhme, Maria ^a   Baggerly, Keith A ^a   Udd, Bjarne ^b   Krahe, Ralf ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Dysregulation; MADS domain transcription enhancer factor 2; MEF2; Myotonic dystrophy; Splicing

Indexed keywords

ISOPROTEIN;

ALTERNATIVE RNA SPLICING; ARTICLE; EXON; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; MEF2A GENE; MEF2B GENE; MEF2C GENE; MEF2D GENE; MUTATION; MYOTONIC DYSTROPHY; NEUROMUSCULAR DISEASE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

GENE EXPRESSION; HUMANS; MADS DOMAIN PROTEINS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES; MYOGENIC REGULATORY FACTORS; MYOTONIA CONGENITA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA SPLICING; TISSUE ARRAY ANALYSIS;

EID: 78649678984     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21789     Document Type: Article

References (43)

1. Olson EN, Perry M, Schulz RA. Regulation of muscle differentiation by the MEF2 family of MADS box transcription factors. Dev Biol 1995;172:2-14.
2. McKinsey TA, Zhang CL, Olson EN. MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem Sci 2002;27:40-47.
3. Potthoff MJ, Olson EN. MEF2: a central regulator of diverse developmental programs. Development 2007;134:4131-4140.
4. Black BL, Olson EN. Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Annu Rev Cell Dev Biol 1998;14:167-196.
5. Leifer D, Krainc D, Yu YT, McDermott J, Breitbart RE, Heng J, et al. MEF2C, a MADS/MEF2-family transcription factor expressed in a laminar distribution in cerebral cortex. Proc Natl Acad Sci USA 1993;90:1546-1550. (Pubitemid 23058210)
6. Xu J, Gong NL, Bodi I, Aronow BJ, Backx PH, Molkentin JD. Myocyte enhancer factors 2A and 2C induce dilated cardiomyopathy in transgenic mice. J Biol Chem 2006;281:9152-9162.
7. Shul'man VA, Shnaider NA, Kozulina EA, But'ianov RA, Sviderskaia LA. Peculiarities of cardiac involvement in patients with dystrophic myotonia [in Russian]. Kardiologiia 2008;48:89-92.
8. Schara U, Schoser BG. Myotonic dystrophies type 1 and 2: a summary on current aspects. Semin Pediatr Neurol 2006;13:71-79. (Pubitemid 44486821)
9. Harper PS. Myotonic dystrophy. London: W.B. Saunders; 2001.
10. Krahe R, Bachinski LL, Udd B. Myotonic dystrophy type 2: clinical and genetic aspects. In: Wells RD, Ashizawa T, editors. Genetic instabilities and neurological diseases: Academic Press/Elsevier; 2006. p 131-150
11. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 30 end of a transcript encoding a protein kinase family member. Cell 1992;68:799-808.
12. Fu YH, Pizzuti A, Fenwick RG Jr, King J, Rajnarayan S, Dunne PW, et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 1992;255:1256-1258.
13. Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, Jansen G, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 30 untranslated region of the gene. Science 1992;255:1253-1255.
14. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001;293:864-867. (Pubitemid 32743976)
15. Groh WJ, Groh MR, Saha C, Kincaid JC, Simmons Z, Ciafaloni E, et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med 2008;358:2688-2697. (Pubitemid 351860861)
16. Akar FG, Tomaselli GF. Conduction abnormalities in nonischemic dilated cardiomyopathy: basic mechanisms and arrhythmic consequences. Trends Cardiovasc Med 2005;15:259-264.
17. Carpenter S, Karpati G. Pathology of skeletal muscle. New York: Oxford University Press; 2001.
18. Vihola A, Bachinski LL, Sirito M, Olufemi SE, Hajibashi S, Baggerly KA, et al. Differences in aberrant expression and splicing of sarcomeric proteins in the myotonic dystrophies DM1 and DM2. Acta Neuropathol 2010;119:465-479.
19. Lin X, Miller JW, Mankodi A, Kanadia RN, Yuan Y, Moxley RT, et al. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Genet 2006;15:2087-2097.
20. Bachinski LL, Udd B, Meola G, Sansone V, Bassez G, Eymard B, et al. Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/ proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect. Am J Hum Genet 2003;73:835-848.
21. Udd B, Meola G, Krahe R, Thornton C, Ranum LP, Bassez G, et al. 140th ENMC International Workshop: Myotonic dystrophy DM2/ PROMM and other myotonic dystrophies with guidelines on management. Neuromuscul Disord 2006;16:403-413. (Pubitemid 43884790)
22. Cheung HC, Baggerly KA, Tsavachidis S, Bachinski LL, Neubauer VL, Nixon TJ, et al. Global analysis of aberrant pre-mRNA splicing in glioblastoma using exon expression arrays. BMC Genomics 2008;9:216. (Pubitemid 351785140)
23. Sallinen R, Vihola A, Bachinski LL, Huoponen K, Haapasalo H, Hackman P, et al. New methods for molecular diagnosis and demonstration of the (CCTG)n mutation in myotonic dystrophy type 2 (DM2). Neuromuscul Disord 2004;14:274-283.
24. Zhu B, Ramachandran B, Gulick T. Alternative pre-mRNA splicing governs expression of a conserved acidic transactivation domain in myocyte enhancer factor 2 factors of striated muscle and brain. J Biol Chem 2005;280:28749-28760. (Pubitemid 41105776)
25. Janson CG, Chen Y, Li Y, Leifer D. Functional regulatory regions of human transcription factor MEF2C. Brain Res Mol Brain Res 2001; 97:70-82.
26. Spangenburg EE, Booth FW. Molecular regulation of individual skeletal muscle fibre types. Acta Physiol Scand 2003;178:413-424.
27. Chin ER, Olson EN, Richardson JA, Yang Q, Humphries C, Shelton JM, et al. A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev 1998;12:2499-2509.
28. Wu H, Rothermel B, Kanatous S, Rosenberg P, Naya FJ, Shelton JM, et al. Activation of MEF2 by muscle activity is mediated through a calcineurin- dependent pathway. EMBO J 2001;20:6414-6423.
29. Wu H, Olson EN. Activation of the MEF2 transcription factor in skeletal muscles from myotonic mice. J Clin Invest 2002;109:1327-1333.
30. Hawke TJ, Atkinson DJ, Kanatous SB, Van der Ven PF, Goetsch SC, Garry DJ. Xin, an actin binding protein, is expressed within muscle satellite cells and newly regenerated skeletal muscle fibers. Am J Physiol Cell Physiol 2007;293:C1636-1644.
31. Peault B, Rudnicki M, Torrente Y, Cossu G, Tremblay JP, Partridge T, et al. Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol Ther 2007;15:867-877. (Pubitemid 46621645)
32. Osborne RJ, Thornton CA. RNA-dominant diseases. Hum Mol Genet 2006;15(Spec No)2:R162-R169.
33. Wheeler TM, Thornton CA. Myotonic dystrophy: RNA-mediated muscle disease. Curr Opin Neurol 2007;20:572-576.
34. Tiwari S, Zhang Y, Heller J, Abernethy DR, Soldatov NM. Atherosclerosis- related molecular alteration of the human CaV1.2 calcium channel alpha1C subunit. Proc Natl Acad Sci USA 2006;103: 17024-17029.
35. Barnes JL, Torres ES, Mitchell RJ, Peters JH. Expression of alternatively spliced fibronectin variants during remodeling in proliferative glomerulonephritis. Am J Pathol 1995;147:1361-1371.
36. Gidh-Jain M, Huang B, Jain P, Battula V, el-Sherif N. Reemergence of the fetal pattern of L-type calcium channel gene expression in non infarcted myocardium during left ventricular remodeling. Biochem Biophys Res Commun 1995;216:892-897.
37. Huang B, El-Sherif T, Gidh-Jain M, Qin D, El-Sherif N. Alterations of sodium channel kinetics and gene expression in the postinfarction remodeled myocardium. J Cardiovasc Electrophysiol 2001;12: 218-225.
38. Karosi T, Szalmas A, Csomor P, Konya J, Petko M, Sziklai I. Disease-associated novel CD46 splicing variants and pathologic bone remodeling in otosclerosis. Laryngoscope 2008;29:1043-1044.
39. Keller KE, Kelley MJ, Acott TS. Extracellular matrix gene alternative splicing by trabecular meshwork cells in response to mechanical stretching. Invest Ophthalmol Vis Sci 2007;48:1164-1172.
40. Mankodi A, Logigian E, Callahan L, McClain C, White R, Henderson D, et al. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 2000;289:1769-1773.
41. Kanadia RN, Johnstone KA, Mankodi A, Lungu C, Thornton CA, Esson D, et al. A muscleblind knockout model for myotonic dystrophy. Science 2003;302:1978-1980.
42. Osborne RJ, Lin X, Welle S, Sobczak K, O'Rourke JR, Swanson MS, et al. Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy. Hum Mol Genet 2009;18:1471-1481.
43. Du H, Cline MS, Osborne RJ, Tuttle DL, Clark TA, Donohue JP, et al. Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nat Struct Mol Biol;17:187-193.